Clinical Trials on AQP4+ NMOSD in Hungary

Total 1 results

Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

Spain, Italy, United States, Japan, Poland, Taiwan, Germany, United Kingdom, Hungary, France, Ukraine

3

Subscribe